C4 Therapeutics (CCCC) Return on Capital Employed (2020 - 2026)
C4 Therapeutics' (CCCC) quarterly Return on Capital Employed came in at 35.94% in Q1 2026, up 374.0% year-on-year from 7.58% in Q1 2025, and up 12.89% quarter-over-quarter from 41.26% in Q4 2025.
C4 Therapeutics (CCCC) Return on Capital Employed (2020 - 2026) Analysis & Trends
C4 Therapeutics' Return on Capital Employed history runs 7 years deep, the most recent figure standing at 35.94% for Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 374.0% year-over-year to 35.94% in Q1 2026; TTM through Mar 2026 was 35.94%, a 374.0% increase from a year earlier, with the FY2025 full-year figure at 35.86%, up 177.0% from the prior year.
- Return on Capital Employed advanced to 35.94% in Q1 2026 per CCCC's latest filing, from 41.26% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 20.04% in Q1 2022 and bottomed at 52.96% in Q3 2025.
- The 5-year median for Return on Capital Employed is 37.66% (2024), against an average of 37.12%.
- Across the five-year window, Return on Capital Employed slumped 2140 bps in 2023 and surged 762 bps in 2024, its largest moves.
- Year by year, Return on Capital Employed stood at 32.26% in 2022, then tumbled by 38 bps to 44.57% in 2023, then rose by 16 bps to 37.66% in 2024, then declined by 10 bps to 41.26% in 2025, then gained by 13 bps to 35.94% in 2026.
- Per Business Quant, the three latest CCCC Return on Capital Employed figures stand at 35.94% (Q1 2026), 41.26% (Q4 2025), and 52.96% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | C4 Therapeutics | 460.17 Mn | 224.50 Mn | - | -35.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.94% |
| Dec 31, 2025 | -41.26% |
| Sep 30, 2025 | -52.96% |
| Jun 30, 2025 | -46.90% |
| Mar 31, 2025 | -39.68% |
| Dec 31, 2024 | -37.66% |
| Sep 30, 2024 | -35.59% |
| Jun 30, 2024 | -35.44% |
| Mar 31, 2024 | -40.62% |
| Dec 31, 2023 | -44.57% |
| Sep 30, 2023 | -43.21% |
| Jun 30, 2023 | -42.87% |
| Mar 31, 2023 | -35.93% |
| Dec 31, 2022 | -32.26% |
| Sep 30, 2022 | -24.67% |
| Jun 30, 2022 | -21.46% |
| Mar 31, 2022 | -20.04% |
| Dec 31, 2021 | -18.01% |
| Sep 30, 2021 | -18.27% |
| Jun 30, 2021 | -19.62% |